ATE427990T1 - Verbesserte reinigungsmethode fur viren - Google Patents

Verbesserte reinigungsmethode fur viren

Info

Publication number
ATE427990T1
ATE427990T1 AT03724692T AT03724692T ATE427990T1 AT E427990 T1 ATE427990 T1 AT E427990T1 AT 03724692 T AT03724692 T AT 03724692T AT 03724692 T AT03724692 T AT 03724692T AT E427990 T1 ATE427990 T1 AT E427990T1
Authority
AT
Austria
Prior art keywords
cleaning method
improved virus
virus cleaning
improved
virus
Prior art date
Application number
AT03724692T
Other languages
English (en)
Inventor
Matthew Coffey
Original Assignee
Oncolytics Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29406789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE427990(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncolytics Biotech Inc filed Critical Oncolytics Biotech Inc
Application granted granted Critical
Publication of ATE427990T1 publication Critical patent/ATE427990T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
    • C12N2720/12251—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT03724692T 2002-04-30 2003-04-28 Verbesserte reinigungsmethode fur viren ATE427990T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37727302P 2002-04-30 2002-04-30
US44317603P 2003-01-29 2003-01-29

Publications (1)

Publication Number Publication Date
ATE427990T1 true ATE427990T1 (de) 2009-04-15

Family

ID=29406789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03724692T ATE427990T1 (de) 2002-04-30 2003-04-28 Verbesserte reinigungsmethode fur viren

Country Status (17)

Country Link
US (3) US7223585B2 (de)
EP (1) EP1501921B2 (de)
JP (1) JP2005523722A (de)
AR (1) AR039783A1 (de)
AT (1) ATE427990T1 (de)
AU (1) AU2003229159B2 (de)
BR (1) BR0309659A (de)
CA (1) CA2482512C (de)
DE (1) DE60327069D1 (de)
DK (1) DK1501921T4 (de)
ES (1) ES2323454T5 (de)
HK (1) HK1070670A1 (de)
IL (1) IL164551A (de)
MX (1) MXPA04010603A (de)
NZ (1) NZ535944A (de)
TW (1) TWI317378B (de)
WO (1) WO2003093463A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
JP4558652B2 (ja) * 2003-06-20 2010-10-06 マイクロビクス・バイオシステムズ・インコーポレイテツド ウイルス生産の改善
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
US8373381B2 (en) 2005-04-22 2013-02-12 GM Global Technology Operations LLC DC/DC-less coupling of matched batteries to fuel cells
US10260049B2 (en) 2005-08-01 2019-04-16 Virocure, Inc. Attenuated reovirus
US10668119B2 (en) 2005-08-01 2020-06-02 Virocure, Inc. Attenuated reovirus
ES2377356T3 (es) * 2006-04-20 2012-03-26 Wyeth Llc Procedimiento de purificación para el aislamiento del virus purificado de la estomatitis vesicular de un cultivo celular
US20080131955A1 (en) * 2006-11-30 2008-06-05 Canon U.S. Life Sciences, Inc. Method of Separating Target DNA from Mixed DNA
US10369171B2 (en) 2007-03-13 2019-08-06 Virocure, Inc. Attenuated reoviruses for selection of cell populations
EP2334328A4 (de) * 2008-09-24 2012-08-29 Medimmune Llc Verfahren zur reinigung von viren
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
CN103347535B (zh) 2010-12-02 2015-11-25 昂科利蒂克斯生物科技公司 液体病毒制剂
EA201390812A1 (ru) 2010-12-02 2013-11-29 Онколитикс Байотек Инк. Лиофилизированные вирусные составы
JP6029651B2 (ja) * 2011-04-29 2016-11-24 オンコリティクス バイオテク，インコーポレーテッド ゲル浸透クロマトグラフィーを使用してウイルスを精製する方法
DK2970920T3 (en) 2013-03-15 2018-08-06 Childrens Hospital Philadelphia SCALABLE MANUFACTURING PROCESS FOR MANUFACTURING RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM
FR3014901B1 (fr) 2013-12-17 2017-06-09 Genethon Procede de purification de virus ou vecteurs viraux enveloppes
WO2015106951A1 (en) * 2014-01-14 2015-07-23 Koninklijke Philips N.V. Organic light emitting diode
WO2016130569A1 (en) * 2015-02-09 2016-08-18 Mj Biologics, Inc. A composition comprising pedv antigens and methods for making and using the composition
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
CN107106689A (zh) 2014-11-05 2017-08-29 沃雅戈治疗公司 用于治疗帕金森病的aadc多核苷酸
SG11201703419UA (en) 2014-11-14 2017-05-30 Voyager Therapeutics Inc Modulatory polynucleotides
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
EP3230441A4 (de) 2014-12-12 2018-10-03 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur herstellung von scaav
EP3368054A4 (de) 2015-10-28 2019-07-03 Voyager Therapeutics, Inc. Regulierbare expression unter verwendung des adeno-assoziierten virus (aav)
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR102392236B1 (ko) 2016-05-18 2022-05-03 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
SG11201809643UA (en) 2016-05-18 2018-12-28 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281A1 (de) 2016-08-30 2021-06-09 The Regents of The University of California Verfahren für biomedizinisches targeting und freisetzung sowie vorrichtungen und systeme zur ausführung davon
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
EP3619308A4 (de) 2017-05-05 2021-01-27 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von morbus huntington
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
JP7229989B2 (ja) 2017-07-17 2023-02-28 ボイジャー セラピューティクス インコーポレイテッド 軌道アレイガイドシステム
KR20200044793A (ko) 2017-08-03 2020-04-29 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
JP7502991B2 (ja) 2017-10-16 2024-06-19 ボイジャー セラピューティクス インコーポレイテッド 筋萎縮性側索硬化症（ａｌｓ）の治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
EP3762500A1 (de) 2018-03-06 2021-01-13 Voyager Therapeutics, Inc. Aus insektenzelle hergestellte teilweise selbstkomplementäre aav-genome
EP3793615A2 (de) 2018-05-16 2021-03-24 Voyager Therapeutics, Inc. Gerichtete entwicklung von aav zur verbesserung des tropismus für zns
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
EP3818161A1 (de) 2018-07-02 2021-05-12 Voyager Therapeutics, Inc. Behandlung von amyotropher lateralsklerose und rückenmarksassoziierten erkrankungen
CA3107462A1 (en) 2018-07-24 2020-01-30 Voyager Therapeutics, Inc. Systems and methods for producing gene therapy formulations
EP3861113A1 (de) 2018-10-04 2021-08-11 Voyager Therapeutics, Inc. Verfahren zur messung des titers und der potenz von viralen vektorpartikeln
SG11202107645RA (en) 2019-01-18 2021-08-30 Voyager Therapeutics Inc Methods and systems for producing aav particles
US20220243225A1 (en) 2019-04-29 2022-08-04 Voyager Therapeutics, Inc. SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS
US20220290182A1 (en) 2019-08-09 2022-09-15 Voyager Therapeutics, Inc. Cell culture medium for use in producing gene therapy products in bioreactors
WO2021041485A1 (en) 2019-08-26 2021-03-04 Voyager Therapeutics, Inc. Controlled expression of viral proteins
EP4192514A1 (de) 2020-08-06 2023-06-14 Voyager Therapeutics, Inc. Zellkulturmedium zur verwendung bei der herstellung von gentherapieprodukten in bioreaktoren
EP4301768A2 (de) 2021-03-03 2024-01-10 Voyager Therapeutics, Inc. Kontrollierte expression von viralen proteinen
WO2022187548A1 (en) 2021-03-03 2022-09-09 Voyager Therapeutics, Inc. Controlled expression of viral proteins
WO2024054983A1 (en) 2022-09-08 2024-03-14 Voyager Therapeutics, Inc. Controlled expression of viral proteins

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4721675A (en) 1982-02-01 1988-01-26 Abbott Laboratories Production of hepatitis A virus in vitro utilizing a persistently virus infected cell culture system
JPS6344532A (ja) 1986-08-11 1988-02-25 Biseibutsu Kagaku Kenkyusho:Kk 豚のレオウイルス感染症ワクチン
US5948441A (en) * 1988-03-07 1999-09-07 The Liposome Company, Inc. Method for size separation of particles
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5658779A (en) * 1992-03-20 1997-08-19 Ligochem, Inc. Method of adsorbing viruses from fluid compositions
DZ1706A1 (fr) 1992-08-07 2002-02-17 Merck & Co Inc Vaccin contre le virus de l'hepatite a.
FR2696748B1 (fr) * 1992-10-14 1994-12-30 Pasteur Merieux Serums Vacc Procédé de préparation d'antigènes et de vaccins de l'hépatite A (HAV).
US5614413A (en) * 1993-07-01 1997-03-25 The Uab Research Foundation Encapsidated recombinant poliovirus nucleic acid and methods of making and using same
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
SI0757717T1 (sl) 1994-05-16 2006-08-31 Merck & Co Inc Cepivo proti papilomavirusu
US6146873A (en) 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
US6143548A (en) * 1995-08-30 2000-11-07 Genzyme Corporation Chromatographic purification of adeno-associated virus (AAV)
DE69737107T2 (de) * 1996-11-20 2007-07-12 Introgen Therapeutics Inc., Austin Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
ES2283032T3 (es) 1996-12-13 2007-10-16 Schering Corporation Metodos para purificar virus.
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
US6110461A (en) 1997-08-13 2000-08-29 Oncolytics Biotech Inc. Reovirus for the treatment of neoplasia
GB9804632D0 (en) 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
ES2312447T3 (es) 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
TWI289158B (en) * 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
EP2253701B1 (de) * 2001-03-16 2014-08-13 Oncolytics Biotech Inc. Methode zur Extraktion von Virus aus einer Zellkultur
BR0309659A (pt) 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
HK1070670A1 (en) 2005-06-24
EP1501921A1 (de) 2005-02-02
US20140178969A1 (en) 2014-06-26
MXPA04010603A (es) 2004-12-13
US20070269856A1 (en) 2007-11-22
EP1501921B2 (de) 2012-07-25
US20040005693A1 (en) 2004-01-08
US10167452B2 (en) 2019-01-01
NZ535944A (en) 2007-11-30
EP1501921B1 (de) 2009-04-08
BR0309659A (pt) 2005-02-22
JP2005523722A (ja) 2005-08-11
DE60327069D1 (de) 2009-05-20
CA2482512C (en) 2011-09-20
DK1501921T4 (da) 2012-10-08
IL164551A (en) 2010-05-17
ES2323454T5 (es) 2012-11-14
AR039783A1 (es) 2005-03-02
TW200401829A (en) 2004-02-01
US8685734B2 (en) 2014-04-01
DK1501921T3 (da) 2009-06-22
ES2323454T3 (es) 2009-07-16
TWI317378B (en) 2009-11-21
IL164551A0 (en) 2005-12-18
AU2003229159A1 (en) 2003-11-17
AU2003229159B2 (en) 2008-02-21
WO2003093463A1 (en) 2003-11-13
US7223585B2 (en) 2007-05-29
CA2482512A1 (en) 2003-11-13

Similar Documents

Publication Publication Date Title
ATE427990T1 (de) Verbesserte reinigungsmethode fur viren
NO20054134D0 (no) Renseprosess
IS3028B (is) Þurrkunaraðferð
BRPI0313238A2 (pt) método
NO20022644D0 (no) Renseprosess
ATE359703T1 (de) Aquakulturverfahren
DE60333210D1 (de) Desinfektionsmethode
NO20035626D0 (no) Metode
NO20035401D0 (no) Metode
NO20023358D0 (no) Metode
DE602004024640D1 (de) Reinigung von titantetrachlorid
FR2841888B1 (fr) Plate-forme de nettoyage
DE602004030793D1 (de) Asynchrones flimmerreduktionsverfahren
ATE377067T1 (de) Aufbrausendes reinigungsmittel
DE10297729T8 (de) Gasreinigungssystem
DE60315267D1 (de) Gereinigte citalopram salze
SE0202568D0 (sv) New process
SE0201004D0 (sv) New process
SE0201363D0 (sv) Novel process
SE0202041D0 (sv) Novel process
SE0301477D0 (sv) New process
SE0302380D0 (sv) New process
SE0301478D0 (sv) New process
DE60335299D1 (de) Verbrennungsverfahren
SE0302575L (sv) Bearbetningsmetod

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties